跳至主要内容
临床试验/NCT00737841
NCT00737841Unknown不适用

Effect of Bifidobacterium on Irritable Bowel Syndrome

Tohoku University1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2006年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
50
试验地点
1
主要终点
Adequate relief and SIBSQ

研究概览

简要总结

There has been no data on effect of Bifidobacterium breve on symptoms of patients with irritable bowel syndrome (IBS). We hypothesized that Bifidobacterium breve is effective on symptoms of IBS patients.

详细描述

There has been no data on effect of Bifidobacterium breve on symptoms of patients with irritable bowel syndrome (IBS). We hypothesized that Bifidobacterium breve is effective on symptoms of IBS patients. IBS patients will be enrolled via advertisement. Any IBS subtypes will not be rejected. They will take either 1.0 g of Bifidobacterium breve 3 times a day or same amount of placebo for 8 weeks. IBS symptoms and allied markers will be checked before, during, and after the administration.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of IBS with Rome II definition

排除标准

  • Diagnosis of serious diseases (both physically and mentally)

研究组 & 干预措施

A

Experimental

Bifidobacterium breve

干预措施: Bifidobacterium breve (Drug)

B

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Adequate relief and SIBSQ

时间窗: 2, 0, 2, 4, 8 weeks during treatment and 4 weeks after treatment

次要结局

  • Psychometric test, bowel gas, blood, and feces.(2, 0, 2, 4, 8 weeks during treatment and 4 weeks after treatment)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验